Literature DB >> 32479784

High Prevalence of Deep Vein Thrombosis in Mechanically Ventilated COVID-19 Patients.

Sebastian Voicu, Philippe Bonnin, Alain Stépanian, Benjamin G Chousterman, Arthur Le Gall, Isabelle Malissin, Nicolas Deye, Virgine Siguret, Alexandre Mebazaa, Bruno Mégarbane.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32479784      PMCID: PMC7260513          DOI: 10.1016/j.jacc.2020.05.053

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


× No keyword cloud information.
Patients with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pneumonia with SARS-CoV-2 present with coagulation disorders and marked susceptibility to thrombosis (1,2). However, the exact prevalence of deep vein thrombosis (DVT) has been poorly investigated, although the risk seems increased in intensive care unit (ICU) patients (3). Therefore, we decided to perform routine duplex ultrasound examination of the lower limb veins systematically in order to administer appropriate anticoagulation in all intubated and mechanically ventilated patients with SARS-CoV-2 pneumonia. We conducted a prospective observational study in the medical and surgical critical care departments of Lariboisière University Hospital, Paris, France. Consecutive adults receiving invasive mechanical ventilation for SARS-CoV-2 pneumonia were included. Patients with previously diagnosed DVT or pulmonary embolism were excluded. During the hospital stay, prophylactic anticoagulation was administered as daily subcutaneous 4,000 IU enoxaparin and, if the glomerular filtration rate was <15 ml/min, as continuous intravenous infusion of daily 15,000 IU unfractionated heparin. Duplex ultrasonography and plasma D-dimer assessment (STA-Liatest-DDI-Plus, Stago, Asnières sur Seine, France) were performed in all patients during the first week of ICU admission. In patients without DVT on the initial ultrasound, a second ultrasound examination was performed ∼7 days later. Quantitative variables are expressed as median (interquartile range) and categoric variables as percentages. The study was part of the French coronavirus disease 2019 cohort registry and was approved by our institutional ethics committee (IDRCB, 2020-A00256-33; CPP, 11-20 20.02.04.68737). When possible, signed informed consent was obtained from the patients or the next of kin. From March 13 to April 3, 2020, 56 patients with SARS-CoV-2 pneumonia were included. Most of the patients were male (75%) with hypertension (46%), diabetes (45%), obesity (30%), and ischemic heart disease (20%). They required vasopressors in 32% of the cases. Prophylactic anticoagulation using enoxaparin or unfractionated heparin was administered in 41 patients (73%) and 8 patients (14%), respectively. Therapeutic anticoagulation was used in 7 patients (13%) to treat atrial fibrillation (n = 2) and manage extracorporeal membrane oxygenation (n = 5). The initial ultrasound was performed 3 days (interquartile range: 2 to 4 days) post-intubation, corresponding to 10 days (interquartile range: 8 to 13 days) after the onset of the first symptoms. Twenty (36%) patients had DVT, among which 11 (20%) cases were proximal (popliteal or femoral) DVT. A second ultrasound examination was performed in 17 patients 8 days (interquartile range: 5 to 9 days) post-intubation, corresponding to 14 days (interquartile range: 11 to 15 days) after the first symptoms. Six patients (35%) acquired DVT; 2 (12%) cases were proximal despite prophylactic anticoagulation in 3 patients and therapeutic anticoagulation in the other 3. Overall, 26 of 56 patients (46%) were diagnosed with DVT, either proximal (n = 13, 23%) or calf (n = 13, 23%) (Figure 1 ). DVT patients had significantly higher plasma D-dimer compared with non-DVT patients (7,210 ng/ml [interquartile range: 3,770 to 13,550 ng/ml] vs. 2,225 ng/ml [interquartile range: 1,195 to 3,630 ng/ml], p = 0.0002) with no significant difference in plasma fibrinogen (7.4 g/l [interquartile range: 5.8 to 8.9 g/l] vs. 7.6 g/l [interquartile range: 5.5 to 8.5 g/l], p = 0.7).
Figure 1

DVT and Plasma D-dimer in 56 Mechanically Ventilated SARS-CoV-2 Patients

(Left) Study groups as percentages of the total (numbers) according to the deep vein thrombosis (DVT) presence and site at the initial and second ultrasound. Color significance is detailed in the figure. (Right)Diamonds represent individual concentrations of D-dimer at the initial ultrasound according to the DVT presence and site, with the same color significance as in the left panel. In the “No DVT” group, the salmondiamonds and the light bluediamonds represent D-dimer in patients who developed femoral and calf DVT, respectively, at the second ultrasound. ∗Missing D-dimer in 1 patient with popliteal DVT at the second ultrasound. SARS-CoV-2 = severe acute respiratory syndrome-coronavirus-2.

DVT and Plasma D-dimer in 56 Mechanically Ventilated SARS-CoV-2 Patients (Left) Study groups as percentages of the total (numbers) according to the deep vein thrombosis (DVT) presence and site at the initial and second ultrasound. Color significance is detailed in the figure. (Right)Diamonds represent individual concentrations of D-dimer at the initial ultrasound according to the DVT presence and site, with the same color significance as in the left panel. In the “No DVT” group, the salmondiamonds and the light bluediamonds represent D-dimer in patients who developed femoral and calf DVT, respectively, at the second ultrasound. ∗Missing D-dimer in 1 patient with popliteal DVT at the second ultrasound. SARS-CoV-2 = severe acute respiratory syndrome-coronavirus-2. Studies have reported a highly variable prevalence of DVT (between 2.0% [2] and 14.8% [3]) in ICU patients, most likely because of the absence of consistent screening. To the best of our knowledge, this is the first study performing systematic ultrasound examination for DVT diagnosis, thus providing data free of selection biases. Our data showed a remarkably high DVT prevalence (46%) and revealed the rapid time course of thrombus formation despite prophylactic anticoagulation. Importantly, 50% of the DVTs were popliteal or femoral, which are most often associated with thromboembolic events, consistent with the unexpectedly high number of pulmonary embolisms (21%) reported in SARS-CoV-2 pneumonia patients admitted to the ICU and occurring within a median time from ICU admission of 6 days (interquartile range: 1 to 18 days) (4). Our data suggest that close monitoring of DVT occurrence is necessary in mechanically ventilated SARS-CoV-2 patients, and because ultrasound may not always be available, especially in epidemic settings, larger studies may investigate the diagnostic performance of D-dimers for DVT diagnosis in these patients. Moreover, the intensity of anticoagulation may need to be reconsidered based on future investigations to ensure more effective prevention (1). In conclusion, we demonstrated a very high DVT prevalence including a high proportion of potentially life-threatening proximal DVT in mechanically ventilated SARS-CoV-2 patients despite standard prophylactic anticoagulant treatment, suggesting the need for close DVT monitoring and assessment of the risks/benefits of more intense anticoagulation regimens in this population.
  36 in total

Review 1.  Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19.

Authors:  Lucas C Godoy; Ewan C Goligher; Patrick R Lawler; Arthur S Slutsky; Ryan Zarychanski
Journal:  CMAJ       Date:  2020-08-16       Impact factor: 8.262

2.  Therapeutic Anticoagulation May Be Associated with Reduced 14-day Mortality in Mechanically Ventilated Patients with COVID-19.

Authors:  Randi Jenkins; Sahil Sheth; Breanne Nestor; Adrien Mazer
Journal:  Innov Pharm       Date:  2021-06-10

3.  High risk of pulmonary embolism in acute respiratory distress syndrome related to COVID-19: an observational controlled-cohort study.

Authors:  Victor de Roubin; Faustine Reynaud; Rémi Coudroy; Maeva Rodriguez; Grégoire Monseau; Florent Joly; Justine Bardin; Florence Boissier; Delphine Chatellier; Anne Veinstein; René Robert; Jean-Pierre Frat; Arnaud W Thille
Journal:  Ann Transl Med       Date:  2021-04

4.  Unexpected acute pulmonary embolism in an old COVID-19 patient with warfarin overdose: a case report.

Authors:  Maxime Coutrot; Maxime Delrue; Bérangère S Joly; Virginie Siguret
Journal:  Eur Heart J Case Rep       Date:  2021-06-05

5.  A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy.

Authors:  Julie Goswami; Taleen A MacArthur; Meera Sridharan; Rajiv K Pruthi; Robert D McBane; Thomas E Witzig; Myung S Park
Journal:  Shock       Date:  2021-06-01       Impact factor: 3.533

Review 6.  Screening for venous thromboembolism in patients with COVID-19.

Authors:  Christophe Vandenbriele; Diana A Gorog
Journal:  J Thromb Thrombolysis       Date:  2021-05-21       Impact factor: 2.300

7.  White blood count, D-dimers, and ferritin levels as predictive factors of pulmonary embolism suspected upon admission in noncritically ill COVID-19 patients: The French multicenter CLOTVID retrospective study.

Authors:  Joris Galland; Benjamin Thoreau; Maxime Delrue; Marie Neuwirth; Alain Stepanian; Anthony Chauvin; Azeddine Dellal; Olivier Nallet; Melanie Roriz; Mathilde Devaux; Jonathan London; Gonzague Martin-Lecamp; Antoine Froissart; Nouara Arab; Bertrand Ferron; Marie-Helene Groff; Viviane Queyrel; Christine Lorut; Lucile Regard; Emilie Berthoux; Guillaume Bayer; Chloe Comarmond; Bertrand Lioger; Arsène Mekinian; Tali-Anne Szwebel; Thomas Sené; Blanca Amador-Boreiro; Olivier Mangin; Pierre-Olivier Sellier; Stephane Mouly; Jean-Philippe Kevorkian; Virginie Siguret; Dominique Vodovar; Damien Sene
Journal:  Eur J Haematol       Date:  2021-05-24       Impact factor: 3.674

Review 8.  Theoretical benefits of yogurt-derived bioactive peptides and probiotics in COVID-19 patients - A narrative review and hypotheses.

Authors:  Ahmed S Gouda; Fatima G Adbelruhman; Hamedah Sabbah Alenezi; Bruno Mégarbane
Journal:  Saudi J Biol Sci       Date:  2021-06-18       Impact factor: 4.052

Review 9.  Incidence of thrombotic complications in COVID-19 : On behalf of ICODE: The International COVID-19 Thrombosis Biomarkers Colloquium.

Authors:  William J Jenner; Diana A Gorog
Journal:  J Thromb Thrombolysis       Date:  2021-05-28       Impact factor: 2.300

Review 10.  Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic.

Authors:  Benjamin Marchandot; Antonin Trimaille; Anais Curtiaud; Kensuke Matsushita; Laurence Jesel; Olivier Morel
Journal:  J Thromb Thrombolysis       Date:  2020-11       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.